Latest news

• Concordia accused of overcharging NHS for thyroid drug

  The pharma firm said to have ‘abused’ its position within the UK market. ... Last December, Pfizer and Flynn Pharma were ordered to pay £84m after being accused of charging excessive and unfair prices for anti-epilepsy treatment phenytoin sodium

• MSD probed by UK for blocking Remicade biosimilars

  The action is the latest in a series launched by the CMA into the pharma industry. ... Last year it fined Pfizer £84m for conspiring with Flynn Pharma to raise the price of epilepsy drug phenytoin, and has since launched an investigation into the

• EU starts investigation of Aspen's cancer drug pricing

  The European Commission said it was looking into concerns that the South African pharma company had "engaged in excessive pricing" for the five drugs - with reports that some drugs had their ... Last December, Pfizer was fined £84m by the Competitions

• Pfizer gets record £84m fine for hiking price of epilepsy drug

  The Competition and Markets Authority (CMA) has levied an £84.2m fine on Pfizer - as well as a £5.2m penalty for distributor Flynn Pharma - saying they hiked the price of ... increase for toxoplasmosis drug Daraprim (pyrimethamine) prompted a public

• Pfizer and Flynn accused of overcharging for epilepsy drug

  Pfizer and Flynn Pharma are under investigation amid claims they charged "excessive and unfair" prices for a widely-used epilepsy drug in the UK. ... the UK distribution rights to Flynn Pharma in 2012, which promptly de-branded the product.